A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters
Discover our longstanding love for gardening and how it started with Schatzi’s chives.
Search
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Sustainable cattle production: Feeding the world while minimizing environmental effect
Sustainable cattle production: Feeding the world while minimizing environmental effect
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
Full data announced in DINAMO trial in young people with T2D
Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.
Shelter Bowl: These pets looking for a new home were the big winners
Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
The View from Both Sides of the Table
The View from Both Sides of the Table
Striving to revolutionize mental health research
World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
Community Guidelines
We welcome your comments and posts and look forward to a dialogue about science & health and our commitment to bring More Health to people around the world.
Connecting our employees to nonprofits that help people around the world
Learn about the new online tool that we’re using to help our employees connect with nonprofits that are providing critical services to communities, choose volunteer activities in their field, and lend their expertise to those in need.
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Cookie Statement
Cookie Statement
FDA accepts Jardiance sNDA for T2D in children 10 and older
The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes
Our Partners: University of Georgia USA
Our Partners: University of Georgia USA
Onboarding
Onboarding
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.